Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (197)	11/5/2000 5:45:16 PM
From: tnsaf	Respond to of 226

From Nature Biotechnology November 2000 Volume 18 Number 11 pp 1185 - 1190 Enhancement of tumor necrosis factor antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Flavio Curnis, Angelina Sacchi, Laura Borgna, Fulvio Magni, Anna Gasparri & Angelo Corti Department of Biological and Technological Research, San Raffaele H Scientific Institute, via Olgettina 58, 20132 Milan, Italy. Correspondence should be addressed to A Corti. e-mail: corti.angelo@hsr.it The clinical use of tumor necrosis factor (TNF) as an anticancer drug is limited to local treatments because of its dose-limiting systemic toxicity. We show here that murine TNF fused with CNGRC peptide (NGR-TNF), an aminopeptidase N (CD13) ligand that targets activated blood vessels in tumors, is 12–15 times more efficient than murine TNF in decreasing the tumor burden in lymphoma and melanoma animal models, whereas its toxicity is similar. Similarly, human NGR-TNF induced stronger antitumor effects than human TNF, even with 30 times lower doses. Coadministration of murine NGR-TNF with a CNGRC peptide or an anti-CD13 antibody markedly decreased its antitumor effects. Tumor regression, induced by doses of murine NGR-TNF lower than the LD50, was accompanied by protective immunity. In contrast, no cure was induced by TNF at any dose. These results suggest that targeted delivery of TNF to CD13 may enhance its immunotherapeutic properties. Moreover, these findings reveal the potential of tumor homing peptides to generate a new class of recombinant cytokines that compared to immunocytokines have a simpler structure, could be easier to produce and are potentially less immunogenic.

To: Jim Oravetz who wrote (197)	11/8/2000 12:41:56 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 226

SuperGen Says Decitabine May Play Significant Cancer Role Dow Jones Newswires SAN RAMON, Calif. -- SuperGen Inc. (SUPG) said data from several studies show that its decitabine may play a "significant role" in the future therapy of hematologic and solid cancers. The data was presented at Mount Sinai School of Medicine's XVIII Chemotherapy Foundation Symposium. In a press release Wednesday, SuperGen said three studies of decitabine to treat myelodysplastic syndrome in 125 patients showed an overall response rate of 49%. An additional study using decitabine to treat chronic myelogenous leukemia in 81 patients had a 62% response rate among patients in chronic phase of the disease. On Nov. 2, the company said decitabine generated a response in 100% of the patients tested in a Phase I/II clinical study designed to establish safety and efficacy in the treatment of sickle cell anemia Jim